TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03299725
Drug: colloidal bismuth sub-citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
Study: NCT04290325
Drug: HMPL-453
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-453 tablet
Study: NCT03013790
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Melatonin at 2 different doses or a placebo
Study: NCT04165135
Drug: Standard of Care for Haemophilia A
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
Study: NCT02703896
Drug: Drug either PPIS or H2RA and prokinetics
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
Study: NCT03132974
Drug: Sogyeonghwalhyeol-tang granule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sogyeonghwalhyeol-tang herbal extract granule
Study: NCT01111682
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic saline continuous infusion, with intermittent boluses as needed
Study: NCT00778726
Drug: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01420042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemon flavoured cordial and Water for Injection
Study: NCT03062397
Drug: JPI-289 High-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: JPI-289 High dose will be intravenously administered during 24 hours
Study: NCT03062397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
Study: NCT02079298
Drug: 2. Treatment with both fluconazole and Ibuprofen.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02756598
Drug: Sufentanil I
Normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus dose of sufentanil 1 microgram/kg
Study: NCT02756598
Drug: Sufentanil II
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus dose of sufentanil 0.5 microgram/kg
Study: NCT02362152
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical field treatment as prescribed by dermatologist
Study: NCT02147392
Drug: [11C]ER-176
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02978612
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
Study: NCT04553003
Drug: Glucocorticoids+hepatoprotectant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.
Study: NCT04553003
Drug: hepatoprotectant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received hepatoprotectants (i.v.gtt.) for 7 days.
Study: NCT02463006
Drug: Porous variant of Bioactive Glass.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap surgery with Porous variant of Bioactive Glass.
Study: NCT02463006
Drug: Non porous variant of Bioactive Glass.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap surgery with non-Porous variant of Bioactive Glass.
Study: NCT00240656
Drug: spironolactone captopril carvedilol
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03142256
Drug: Truvada 200Mg-300Mg Tablet
Normalized name: Truvada 200mg-300mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
Study: NCT01826045
Drug: Poly-gamma Glutamic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01826045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01084213
Drug: Intermittent screening and treatment of malaria in pregnancy (IST)
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
Study: NCT01084213
Drug: SP-IPTp
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
Study: NCT02779270
Drug: BAY987518
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104
Study: NCT04697654
Drug: TLC19 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
Study: NCT04108208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally.
Study: NCT04108208
Drug: Androgen-deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Study: NCT04026711
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 12 weeks
Study: NCT00636961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo devices and hard gelatin capsules
Study: NCT01588405
Drug: UT-15C SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
Study: NCT01216332
Drug: High-dose trivalent inactivated influenza vaccine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
Study: NCT01216332
Drug: Standard dose trivalent inactivated influenza vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL standard dose trivalent inactivated influenza vaccine
Study: NCT02208050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01486186
Drug: placebo chinese medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
Study: NCT00461097
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for egg white solid
Study: NCT03951753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02801981
Drug: GSK2230672
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
Study: NCT02801981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
Study: NCT00496704
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01741155
Drug: SPI-1620
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-1620 11 μg/m2 administered intravenously over one minute.
Study: NCT03996564
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500mg-1000mg,
Study: NCT03996564
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 50mg-75 mg orally
Study: NCT03996564
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocodone 5mg/325mg-10mg/650mg mg
Study: NCT03996564
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, or intramuscular Ketorolac 30mg-60 mg
Study: NCT01483599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections
Study: NCT02771860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical syringe
Study: NCT00618124
Drug: SU011248; Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
Study: NCT00562731
Drug: ARD-0403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily transdermal ARD-0403
Study: NCT03678675
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
Study: NCT02686788
Drug: TMP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
Study: NCT01681095
Drug: Custodiol HTK
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
Study: NCT01681095
Drug: Cold Blood Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
Study: NCT00564278
Drug: Standard antidepressant therapy (SADT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
Study: NCT03758235
Drug: IncobotulinumtoxinA 100 UNT Injection [Xeomin]
Normalized name: incobotulinumtoxinA 100 UNT Injection [Xeomin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
Study: NCT03758235
Drug: OnabotulinumtoxinA 100 UNT [Botox]
Normalized name: onabotulinumtoxinA 100 UNT [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
Study: NCT03332095
Drug: Antiretroviral (ARV) medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
Study: NCT03900572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection, 3 doses
Study: NCT04582201
Drug: agenT-797
Normalized name: MISCELLANEOUS AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study: NCT02290925
Drug: Kothala Himbutu Biscuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
Study: NCT03688802
Drug: OC-01 (varenicline) nasal spray
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline) nasal spray
Study: NCT03688802
Drug: Placebo (vehicle control) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01633970
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive leucovorin 400 mg/m\^2 IV q2w.
Study: NCT00253370
Drug: BAY 43-9006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01410240
Drug: FLOSEAL Hemostatic Matrix + Standard of care
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used
Study: NCT03699540
Drug: placebo alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental, non-therapeutic administration of inactive alcohol dose(s)
Study: NCT01489852
Drug: 17beta-estradiol
Normalized name: 16alpha-(18F)Fluoro-17beta-estradiol
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
Study: NCT04728984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
Study: NCT04691687
Drug: IV Solution
Normalized name: IV SOLUTIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo comparator
Study: NCT00079885
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03522207
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo per os 30 minutes prior to 2nd PSG
Study: NCT03522207
Drug: placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg placebo per os 30 minutes prior to 3rd PSG
Study: NCT03385551
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol or Promestriene depending on the arm
Study: NCT04242407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Study: NCT01474161
Drug: GFT505 120mg - old formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
Study: NCT01474161
Drug: GFT505 180mg - new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
Study: NCT01474161
Drug: GFT505 240mg - new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
Study: NCT01474161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
Study: NCT00884793
Drug: Study NNRTI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
Study: NCT01324128
Drug: PA21 (2.5 g tablet containing 500 mg iron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Study: NCT02611765
Drug: Benzathine penicillin G intramuscular 7.2 million units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
Study: NCT02611765
Drug: Benzathine penicillin G intramuscular 2.4 million units
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of intramuscular 2.4 million units of benzathine penicillin G
Study: NCT03333486
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00230984
Drug: Oral dietary supplements (563 kcal/d), RESPIFOR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00230984
Drug: 160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00884793
Drug: Study PI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
Study: NCT02794506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
Study: NCT00964405
Drug: GSK233705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Long acting muscarinic receptor antagonist
Study: NCT00964405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02591030
Drug: GEMCIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8.
Study: NCT02591030
Drug: mFolfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1
Study: NCT01324128
Drug: PA21-1 (1.25 g tablet containing 250 mg iron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose comparator (1.25 g/day)
Study: NCT00040144
Drug: ACH126, 433
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02984644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
Study: NCT02829385
Drug: Apatinib and XELOX combined treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.
Study: NCT00311753
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
Study: NCT02009423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00048165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
Study: NCT02282163
Drug: sulphur hexafluoride lipid-type A microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound imaging contrast agent
Study: NCT00426972
Drug: estradiol (Zesteem)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004896
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01812616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).